Evidence map›Paper›PMID 39596160›Full record

ArticleInternational journal of molecular sciences2024

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

Anna Vera de Jonge, Tamás Csikós, Merve Eken, Elianne P Bulthuis, Pino J Poddighe, Margaretha G M Roemer, Martine E D Chamuleau, Tuna Mutis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Special Issue: Antibody Therapy for Hematologic Malignancies.International journal of molecular sciences · 2025
    Article
  2. Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna Vera de JongeDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-5397-1762
Tamás CsikósDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Merve EkenDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Elianne P BulthuisDepartment of Clinical Human Genetics, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Pino J PoddigheDepartment of Clinical Human Genetics, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Margaretha G M RoemerDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Martine E D ChamuleauDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-0123-9182
Tuna MutisDepartment of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In B-cell malignancies, the overexpression of MYC is associated with poor prognosis, but its mechanism underlying resistance to immunochemotherapy remains less clear. In further investigations of this issue, we show here that the pharmacological inhibition of MYC in various lymphoma and multiple myeloma cell lines, as well as patient-derived primary tumor cells, enhances their susceptibility to NK cell-mediated cytotoxicity induced by conventional antibodies targeting CD20 (rituximab) and CD38 (daratumumab), as well as T cell-mediated cytotoxicity induced by the CD19-targeting bispecific T-cell engager blinatumomab. This was associated with upregulation of the target antigen only for rituximab, suggesting additional escape mechanisms. To investigate these mechanisms, we targeted the

Indexed as

T-LymphocytesAntibodies, BispecificAntibodies, MonoclonalAntigens, CD20ApoptosisCell Line, TumorCRISPR-Cas SystemsHumansKiller Cells, NaturalMultiple MyelomaProto-Oncogene Proteins c-mycRituximabTumor EscapeAntibodies, BispecificAntibodies, MonoclonalAntigens, CD20blinatumomabMYC protein, humanProto-Oncogene Proteins c-mycRituximabantibody therapyB-cell malignanciesCRISPR-Cas9immunotherapylymphomaMYCMYC inhibitionT cell-redirecting antibodies

Identifiers

PMID39596160
PMCPMC11594070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.